DxS and Amgen Collaborate on Companion Diagnostic for Vectibix

DxS (Manchester, UK) has signed an agreement with Amgen Inc. (Thousand Oaks, CA, USA) to provide a K-RAS companion diagnostic for Vectibix (panitumumab) in the United States. Financial terms of the agreement were not disclosed.

The companies shall work together to further facilitate the use of Vectibix in metastatic colorectal cancer patients with wild-type K-RAS status in the United States. The ultimate aim of the collaboration is for the TheraScreen: K-RAS mutation kit to be granted U.S. Food and Drug Administration (FDA; Rockville, MD, USA) approval as a companion diagnostic for use with Vectibix.

The agreement follows a collaboration entered into by the parties last year with respect to the TheraScreen: K-RAS mutation kit in Europe.

DxS provides molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. The company has an expanding portfolio of cancer mutation products. The TheraScreen range of clinical diagnostic kits can identify genetic tumor mutations that affect how patients respond to cancer therapies.

Amgen is a human therapeutics company in the biotechnology industry. The company develops novel products based on advances in recombinant DNA and molecular biology. It is a science-driven enterprise dedicated to helping people fight serious illness.

Related Links:
DxS
Amgen
U.S. Food and Drug Administration